Last reviewed · How we verify
alpha-glucosidase inhibitors
At a glance
| Generic name | alpha-glucosidase inhibitors |
|---|---|
| Also known as | oral hypoglycemic agent, acarbose, miglitol, voglibose |
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM (PHASE4)
- Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes (PHASE3)
- Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO) (NA)
- A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients (PHASE3)
- Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes
- A Clinical Safety and Efficacy Study in Subjects With Overweight or Obese Class - I, to Evaluate the Degree of Significant Weight Loss by Regular Intake of Phaseolean (White Kidney Bean Standardized Extract) (NA)
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- alpha-glucosidase inhibitors CI brief — competitive landscape report
- alpha-glucosidase inhibitors updates RSS · CI watch RSS
- Sanofi portfolio CI